26
Participants
Start Date
December 1, 2025
Primary Completion Date
December 1, 2030
Study Completion Date
December 1, 2030
Epcoritamab
"Epcoritamab will be administered via subcutaneous injection at the following dose levels and schedule over a total of twelve cycles:~* Cycle 1 Day 1: Step-up dose of 0.16 mg~* Cycle 1 Day 8: Step-up dose of 0.80 mg~* Cycle 1 Day 15: First full dose of 48 mg.~* Cycles 2 through 4 Days 1, 8 and 15: 48 mg~* Cycles 5 through 12 Days 1 and 15: 48 mg"
Loncastuximab Tesirine
"Loncastuximab will be administered intravenously (IV) at the following dose level and schedule over a total of four cycles:~* Cycles 1 and 2 Day 1: 120 mcg/kg~* Cycles 3 and 4 Day 1: 75 mcg/kg~* Cycle 4 Day 22: 75 mcg/kg"
University of Miami, Miami
Collaborators (2)
ADC Therapeutics S.A.
INDUSTRY
Genmab
INDUSTRY
University of Miami
OTHER